Rx May Offer Hope for Some Non-Hodgkin Lymphoma PatientsdailyRxIndolent NHL is traditionally treated with a targeted therapy called Rituxan (rituximab) and chemotherapy. This treatment is usually effective in the beginning, but the disease is known to …
Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma ForumWall Street JournalAn investigator-sponsored Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoc…
Drug Discovery & Development |
New pill ‘melts away’ leukemia without chemotherapy
UPI.com (blog) … the most common form of the disease. The findings have been published in the New England Journal of Medicine, and show that idelalisib in combination with rituximab could prevent the leukemia from worsening, even in chemotherapy-resistant patients. A Pill ‘Melts Away’ Common Form of LeukemiaHealthNewsDigest.com |
John Theurer Cancer Center Announces Positive Results with New Targeted …Fort Mills TimesThe data presented in NEJM today reports on a single arm open label phase II study, with 125 patients with iNHL refractory to the two most common therapies used …
Drug Discovery & Development |
Twice-daily pill could turn leukemia into a highly treatable disease
Medical Xpress What’s more, just 13 percent of patients treated with rituximab alone responded to the therapy, compared to 81 percent of the participants in the idelalisib treatment group. A higher percentage of patients who received both drugs – some 92 percent … New pill can ‘melt away’ leukemia without chemotherapyANINEWS A Pill ‘Melts Away’ Common Form of LeukemiaHealthNewsDigest.com |
BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization …EIN News (press release)Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metas…
|
A Pill ‘Melts Away’ Common Form of Leukemia
HealthNewsDigest.com They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of … |
Idelalisib could be on the market later this year, pending FDA approvalNews-Medical.netAbout 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combinati…
New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphomaNews-Medical.netAbout 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a co…
MedscapeIdelalisib and rituximab extends survival in CLL patientsThe Oncology Report… rituximab extends survival in CLL patients. Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymph…